Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
(iii) In circumstances in which negative or zero manufacturer's ASP data is reported for all NDCs for a given quarter and either no other biosimilars have been approved for the same reference product or no other biosimilars of the same reference product report positive manufacturer's ASP data for the given quarter, the payment limit for the given quarter is the sum of the following until at least one NDC for the drug has positive manufacturer's ASP data for a quarter: (A) The volume-weighted average of the most recent available positive manufacturer's ASP data from a previous quarter
They are often packaged in portable tins
(e) Estimated Burden for Third Party Intermediary Plan Audits In aggregate, as shown in Table 89, we assume that 89 third party intermediaries will submit plan audits for the CY 2025 performance period/2027 MIPS payment year (35 targeted audits, 28 participation plans, 20 CAPs, and 6 transition plans)
(20) How can the model proactively address concerns related to increased consolidation, ensuring that integration efforts do not lead to reduced ( competition and potential negative impacts on healthcare quality and costs
Therefore, we believe a large majority of provider-basedand some independentRHCs have access to a full-service laboratory, thereby maintaining access to the H&H laboratory test, even if it is no longer required to be provided directly by RHCs
US$ 27.30
US$ 25.09
US$ 27.96
US$ 20.95
US$ 27.40
US$ 26.55
US$ 26.22
US$ 27.63
US$ 25.27
